IP Library Granted Patent US 8,337,861
Granted Patent B2
US 8,337,861 · App. 10/541,614 · Granted Dec 25, 2012

Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,337,861
App. No.
10/541,614
Granted
Dec 25, 2012
Kind
B2
Abstract

The present invention comprises methods for enhancing the immunogenicity of a bacterial vaccine vector and an antigen by passaging the bacterial vaccine vector through an animal.

Claims (12)

1. A method of enhancing the immunogenicity of a bacterial vaccine vector expressing a heterologous antigen, the method comprising the steps of: a) administering to a non-human animal the bacterial vaccine vector; b) passaging the bacterial vaccine vector through the animal; c) harvesting the bacterial vaccine vector from a normal organ or normal tissue in the non-human animal; and d) repeating step a), step b), and step c) with the harvested bacterial vaccine vector until a maximum bacterial load for said vector in said organ or tissue is reached; wherein said maximum bacterial load is reached by the 2 nd passage, wherein said bacterial vector from said maximum bacterial load has reached the maximum bacterial virulence, wherein administering said bacterial vector derived from said maximum bacterial load to a human subject after passaging through said non-human animal results in enhanced immunogenicity of said heterologous antigen in said bacterial vaccine vector, and wherein the bacterial vaccine vector is a Listeria vaccine vector.

2. The method of claim 1 , wherein the organ is a spleen or liver.

3. The method of claim 1 , wherein the antigen is a tumor antigen.

4. The method of claim 1 , wherein the animal is a mammal.

5. The method of claim 4 , wherein the mammal is a mouse.

6. The method of claim 1 , further comprising the step of administering the bacterial vaccine vector to a human via oral or parenteral administration following the step of harvesting the vector after achieving a maximum bacterial load in said non-human animal.

7. A method of enhancing the immunogenicity of an antigen expressed from a bacterial vaccine vector, the method comprising the steps of: a) administering to a non-human animal the bacterial vaccine vector; b) passaging the bacterial vaccine vector through the non-human animal; c) harvesting the bacterial vaccine vector from a normal organ or normal tissue in the non-human animal; and d) repeating step a), step b), and step c) with the harvested bacterial vaccine vector until a maximum bacterial load for said vector in said organ or tissue is reached; wherein said maximum bacterial load is reached by the 2 nd passage, wherein said bacterial vector from said maximum bacterial load has reached the maximum bacterial virulence, wherein administering said bacterial vector derived from said maximum bacterial load to a human subject after passaging through said non-human animal results in enhanced immunogenicity of said heterologous antigen in said bacterial vaccine vector, and wherein the bacterial vaccine vector is a Listeria vaccine vector.

8. The method of claim 7 , wherein the organ is a spleen or liver.

9. The method of claim 7 , wherein the antigen is a tumor antigen.

10. The method of claim 7 , wherein the animal is a mammal.

11. The method of claim 10 , wherein the mammal is a mouse.

12. The method of claim 7 , further comprising the step of administering the bacterial vaccine vector to a human via oral or parenteral administration following the step of harvesting the vector after achieving a maximum bacterial load in said non-human animal.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2014
From: PATERSON, YVONNE; PETERS, CHRISTIAN
To: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Reel/Frame 033163/0125 →
CHANGE OF NAME Recorded Nov 16, 2005
From: YAMANOUCHI PHARMACEUTICAL CO., LTD.
To: ASTELLAS PHARMA INC.
Reel/Frame 016784/0361 →